 | Up a level |
Koeberle, D; Betticher, D C; von Moos, R; Dietrich, D; Brauchli, P; Baertschi, D; Matter, K; Winterhalder, R; Borner, M; Anchisi, S; Moosmann, P; Kollár, Attila; Saletti, P; Roth, A; Frueh, M; Kueng, M; Popescu, R A; Schacher, S; Hess, V and Herrmann, R (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of oncology, 26(4), pp. 709-714. Oxford University Press 10.1093/annonc/mdv011
Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Bühlmann, M; Fehr, M; Schönenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Müller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K; Swiss Group for Clinical Cancer Research, (SAKK) (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, 22(1), pp. 80-5. Oxford: Oxford University Press 10.1093/annonc/mdq319
